Cingulate Inc.
NASDAQ:CINGBiotechnology
-$0.05 today
- Market cap
- $76.46M
- Beta
- -0.91
- P/E (TTM)
- -1.0
- EPS (TTM)
- -$5.10
Volume 0.95M
Average 0.46M
CING Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Cingulate Inc.NASDAQ: CING
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $9.31M (cash outflow) rose 144.9% year over year, ahead of the +69.2% change in trailing-twelve-month net income. Sequentially, it rose 48.4% from the prior quarter. Over 3 fiscal years it compounded at +8.3% a year.
Context
- Net income grew in size in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +144.9% holds above the trailing-twelve-month pace of +69.2%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (22.45M) USD
- Year-over-year change
- -44.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (22.45M) | -44.4% |
| FY2024 | 2024-12-31 | (15.55M) | +33.9% |
| FY2023 | 2023-12-31 | (23.53M) | -33.1% |
| FY2022 | 2022-12-31 | (17.68M) | +14.6% |
| FY2021 | 2021-12-31 | (20.71M) | — |
Net Income vs competitors
How CING compares with its peers on the latest reported figures
- CING's LTM Mar 2026 net income of $27.71M is the largest of the 2 companies compared; the peer median is $7.22M.
- Its year-over-year change of +69.2% is the lowest of 2, against a peer median of +117.3%.
- Over three fiscal years its annual growth of +8.3% compares with a peer median of -1.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $27.71M | +69.2% | +8.3% | — | |
| LTM Mar 2026 | $7.22M | +117.3% | -1.6% | — | |
| Peer median (excluding CING) | $7.22M | +117.3% | -1.6% | — | |
Competitors are the stored peer set for CING. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (20.71M) | (17.68M) | (23.53M) | (15.55M) | (22.45M) |
| Depreciation & Amortization | 708.32K | 394.01K | 582.92K | 653.09K | 540.89K |
| Deferred Income Tax | (16.26M) | (797.96K) | 0 | 0 | 0 |
| Stock-Based Compensation | 12.78M | 800.8K | 812.67K | 995.48K | 0 |
| Change in Working Capital | (3.21M) | 598.62K | 7.1M | (4.55M) | 830.85K |
| Accounts Receivables | (1.86M) | 1.25M | 219.81K | (11.7K) | 18.31K |
| Inventory | 0 | (1.25M) | 0 | 0 | 0 |
| Accounts Payables | 0 | 791.01K | 0 | 0 | 0 |
| Other Working Capital | (1.35M) | (192.39K) | 6.89M | (4.54M) | 812.54K |
| Other Non-Cash Items | 16.26M | 797.96K | 0 | 0 | 3.83M |
| Operating Cash Flow | (10.43M) | (15.88M) | (15.03M) | (18.45M) | (17.25M) |
| Capital Expenditures | (814.74K) | (153.42K) | (224.1K) | (211.8K) | (162.14K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 933 | 0 | 0 | 0 |
| Other Investing Activities | 0 | (165) | 0 | 0 | 138 |
| Investing Cash Flow | (814.74K) | (152.65K) | (224.1K) | (211.8K) | (162K) |
| Debt Repayment | (936.59K) | 4.98M | 2.98M | 4.95M | 6M |
| Common Stock Issued | 20.37M | (85.92K) | 6.97M | 25.88M | 10.15M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 7.1M | 0 | 0 | 0 | (382) |
| Financing Cash Flow | 26.54M | 4.9M | 9.95M | 30.82M | 16.15M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 15.3M | (11.14M) | (5.3M) | 12.16M | (1.26M) |
| Free Cash Flow | (11.25M) | (16.04M) | (15.26M) | (18.66M) | (17.41M) |
Cingulate Inc.
NASDAQ:CING
Intrinsic Alpha fair value
Locked
Current Price
$5.11
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.